{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T13:54:11Z","timestamp":1776434051327,"version":"3.51.2"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with radioactive iodine refractory progressive (RAIR) differentiated thyroid cancer (DTC) often developed resistance after first-line therapy. Apatinib plus camrelizumab is a therapy with promising efficacy in patients with other malignant cancers. Herein, we presented a case of progressive RAIR DTC treated with apatinib plus camrelizumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>We reported a 43-year-old man diagnosed as DTC with metastases in the lungs, the 7th cervical vertebra, and malignant lymph nodes mainly in the mediastinum. While initially showing disease stabilization after giving the first-line multitargeted kinase inhibitor (MKI) therapy, the patient developed progressive disease and was enrolled into a combined therapy with both apatinib and camrelizumab on November 10, 2020. Upon the first 6 months, the combination therapy showed disease control in terms of both stable structural lesions and biochemical thyroglobulin (Tg) level. Six months later, a decrease over the targeted lesions was observed and a partial response (PR) according to RECIST 1.1 criteria was finally achieved upon 12 months\u2019 assessment, followed by the decline in serum Tg level. The main adverse event was occasional diarrhea without treatment interruption.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We reported a case with RAIR DTC that benefited from combination immunotherapy, apatinib plus camrelizumab, after resistance from donafenib. We observed a gradually getting better efficacy and a mild and long duration of this combination therapy and hoped to provide a therapeutic choice for these patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.943916","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T07:35:30Z","timestamp":1659944130000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review"],"prefix":"10.3389","volume":"13","author":[{"given":"Jiayi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuanzhuan","family":"Mu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yansong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(13)70215-8","article-title":"Definition and management of radioactive iodine-refractory differentiated thyroid cancer","volume":"2","author":"Schlumberger","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s82972","article-title":"Selective use of sorafenib in the treatment of thyroid cancer","volume":"10","author":"Pitoia","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/cad.0000000000000247","article-title":"New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond","volume":"26","author":"Wang","year":"2015","journal-title":"Anticancer Drugs"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21010010","article-title":"Multikinase inhibitor treatment in thyroid cancer","volume":"21","author":"Ancker","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2174\/1381612822666160614084943","article-title":"Effects and role of multikinase inhibitors in thyroid cancer","volume":"22","author":"Laursen","year":"2016","journal-title":"Curr Pharm Des"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00332-6","article-title":"Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Brose","year":"2021","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12885-019-5380-3","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer","volume":"19","author":"Mehnert","year":"2019","journal-title":"BMC Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1111\/cas.13806","article-title":"Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model","volume":"109","author":"Kimura","year":"2018","journal-title":"Cancer Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107281","article-title":"Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review","volume":"91","author":"Mo","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002191","article-title":"Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort a report in a multicenter phase Ib\/II trial","volume":"9","author":"Mei","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-2571","article-title":"Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): A nonrandomized, open-label, phase II trial","volume":"27","author":"Xu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100312","article-title":"Camrelizumab plus apatinib in treatment-naive patients with advanced nonsquamous NSCLC: A multicenter, open-label, single-arm, phase 2 trial","volume":"3","author":"Ren","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jtho.2020.10.002","article-title":"Camrelizumab plus apatinib in extensive-stage SCLC (PASSION): A multicenter, two-stage, phase 2 trial","volume":"16","author":"Fan","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01920","article-title":"Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): A multicenter, open-label, single-arm, phase II trial","volume":"38","author":"Lan","year":"2020","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000696","article-title":"Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial","volume":"8","author":"Liu","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000798","article-title":"Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial","volume":"8","author":"Xie","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(21)00378-2","article-title":"Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial","volume":"7","author":"Meng","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B22","article-title":"Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase II trial","author":"Ren","year":"2020","journal-title":"Am J Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00460-5","article-title":"Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial","volume":"22","author":"Cheng","year":"2021","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.646979","article-title":"The efficacy and safety of apatinib plus camrelizumab in patients with previously treated advanced biliary tract cancer: A prospective clinical study","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-2484","article-title":"Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: An open-label, dose escalation and expansion study","volume":"25","author":"Xu","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28060450","article-title":"Combination of lenvatinib and pembrolizumab as salvage treatment for paucicellular variant of anaplastic thyroid cancer: A case report","volume":"28","author":"Luongo","year":"2021","journal-title":"Curr Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0322","article-title":"Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma","volume":"31","author":"Dierks","year":"2021","journal-title":"Thyroid"},{"key":"B28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40425-018-0378-y","article-title":"Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma","volume":"6","author":"Iyer","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.6268","article-title":"Apatinib vs placebo in patients with locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: The REALITY randomized clinical trial","volume":"8","author":"Lin","year":"2022","journal-title":"JAMA Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aak9670","article-title":"Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade","volume":"9","author":"Schmittnaegel","year":"2017","journal-title":"Sci Transl Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-17-0640","article-title":"Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1\/PD-L1 blockade in lung cancer","volume":"7","author":"Zhao","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15036","article-title":"Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-3439","article-title":"Analysis of biomarkers and association with clinical outcomes in patients with differentiated thyroid cancer: Subanalysis of the sorafenib phase III DECISION trial","volume":"25","author":"Brose","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2020_190801N701","article-title":"Adverse events and management of apatinib in patients with advanced or metastatic cancers: A review","volume":"67","author":"Shao","year":"2020","journal-title":"Neoplasma"},{"key":"B37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-020-00886-2","article-title":"Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.943916\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T07:35:34Z","timestamp":1659944134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.943916\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,8]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2022.943916"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.943916","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,8]]},"article-number":"943916"}}